Cel-Sci Corp (CVM)

$9.14 +0.20 (2.24%)
Market Cap 47.57M
Revenue (ttm) 0.00
Net Income (ttm) -26.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 217,300
Avg Vol 975,040
Day's Range N/A - N/A
Shares Out 5.32M
Stochastic %K 67%
Beta 0.52
Analysts Strong Sell
Price Target $180.18

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology
Sector: Healthcare
Phone: 703 506 9460
Website: cel-sci.com
Address:
8229 Boone Boulevard, Suite 802, Vienna, United States
cruiser24
cruiser24 Aug. 7 at 4:00 PM
$CVM THANK You for stating exactly what I have seen while reading the outcome of the longest study of head and neck cancer. Not post of investors but found in medical journals. Like you it sounded like a fantastic opportunity for those confronted with the cancer and looking for the best option of treatment with shown greater outcomes. $CVM BULLISH
0 · Reply
cruiser24
cruiser24 Aug. 7 at 3:41 PM
Seems like a lot of different ones repeating Cel/sci. You know what they say. Where there is smoke there is fire. I sure am ready to roast me some hotdogs and marshmallows. $CVM BULLISH
1 · Reply
SmallCapGrowth
SmallCapGrowth Aug. 7 at 3:39 PM
$CVM CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules https://finance.yahoo.com/news/cel-sci-announces-closing-5-200500941.html
1 · Reply
cruiser24
cruiser24 Aug. 7 at 2:48 PM
$CVM
0 · Reply
cruiser24
cruiser24 Aug. 7 at 2:42 PM
$CVM I realize this article is old but it was published by Market screener not Cel-sci. It could be very damaging false reporting investor news I would think. IMO it is significant that this partnership is being reported by others besides Cel-sci Corporation only. It describes the details of the partnership in more detail as well. I’m not giving this as investor advice . Just thought it was worth noticing.
1 · Reply
Thebullrun
Thebullrun Aug. 7 at 2:13 PM
$CVM
1 · Reply
SmallCapGrowth
SmallCapGrowth Aug. 7 at 1:56 PM
$CVM CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules https://finance.yahoo.com/news/cel-sci-announces-closing-5-200500941.html #STOCKS #STOCKSTOBUY #INVESTORS #STOCKS #TRADER #CVM @Charles
1 · Reply
CashNCarry
CashNCarry Aug. 7 at 12:25 PM
$CVM
0 · Reply
Bjfrank87
Bjfrank87 Aug. 7 at 11:38 AM
$CVM the chart is screaming next move. A move upwards is needed to keep things looking bullish. Really hoping we don’t see a stop loss raid. A move back above $10 would be awesome.
0 · Reply
phoenix31415
phoenix31415 Aug. 7 at 8:39 AM
$CVM Yesterday's daily short sale volume was 51.25% (as reported by FINRA) and it seems that the shorts are trying hard to manipulate the market but the PPS went up 2.24%! The short borrow fee is at 56.26%!! and the number of currently shorted shares has dramatically increased to 1.54 million shares — that is an incredible 30.39% of the Float!! Furthermore, the short shares availability is down to 35000 shares. Note that on Fintel's Short Squeeze Leaderboard of the top 250 stocks most likely to squeeze, CVM is listed as #2!! With the recent SFDA and partner developments, it should just be a matter of time until Multikine will be approved and the heavy manipulation by the shorts will come to an end. I am so happy for all the cancer patients who will hopefully soon be able to profit from Multikine! GLTAL!!
1 · Reply
Latest News on CVM
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

Jul 14, 2025, 4:05 PM EDT - 23 days ago

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

Jul 11, 2025, 12:16 PM EDT - 27 days ago

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Jul 11, 2025, 9:15 AM EDT - 27 days ago

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

Jun 18, 2025, 9:00 AM EDT - 7 weeks ago

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

CEL-SCI Announces Closing of Public Offering

May 23, 2025, 4:05 PM EDT - 2 months ago

CEL-SCI Announces Closing of Public Offering

CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:14 PM EDT - 2 months ago

CEL-SCI Announces Pricing of Public Offering

CEL-SCI Announces Proposed Public Offering

May 21, 2025, 4:05 PM EDT - 2 months ago

CEL-SCI Announces Proposed Public Offering

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 21, 2025, 8:00 AM EDT - 2 months ago

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

CEL-SCI Announces Combination of Common Stock

May 19, 2025, 2:40 PM EDT - 2 months ago

CEL-SCI Announces Combination of Common Stock

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

May 15, 2025, 9:00 AM EDT - 3 months ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Apr 23, 2025, 8:30 AM EDT - 3 months ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Apr 8, 2025, 9:51 AM EDT - 4 months ago

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Mar 24, 2025, 9:00 AM EDT - 4 months ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

CEL-SCI Announces Closing of $2.5 Million Offering

Mar 18, 2025, 4:05 PM EDT - 5 months ago

CEL-SCI Announces Closing of $2.5 Million Offering

CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 5 months ago

CEL-SCI Announces Pricing of $2.5 Million Offering

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Mar 17, 2025, 8:00 AM EDT - 5 months ago

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Mar 14, 2025, 8:30 AM EDT - 5 months ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 20, 2025, 8:00 AM EST - 6 months ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Feb 18, 2025, 8:30 AM EST - 6 months ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Jan 14, 2025, 9:00 AM EST - 7 months ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

CEL-SCI Announces Closing of $5 Million Offering

Dec 31, 2024, 4:05 PM EST - 7 months ago

CEL-SCI Announces Closing of $5 Million Offering

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 29, 2024, 8:41 PM EST - 7 months ago

CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 27, 2024, 5:05 PM EST - 7 months ago

CEL-SCI Announces Proposed Public Offering of Common Stock

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Dec 12, 2024, 9:15 AM EST - 8 months ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Stock Picks From Seeking Alpha's October 2024 New Analysts

Nov 8, 2024, 8:00 AM EST - 9 months ago

Stock Picks From Seeking Alpha's October 2024 New Analysts

ACGL AMCX AMPS APOG AVRE BHP BILL

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Nov 7, 2024, 8:15 AM EST - 9 months ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 22, 2024, 9:15 AM EDT - 10 months ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Oct 1, 2024, 6:00 AM EDT - 11 months ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 16, 2024, 7:30 AM EDT - 11 months ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 10, 2024, 9:32 AM EDT - 11 months ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Sep 4, 2024, 9:00 AM EDT - 1 year ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

CEL-SCI Announces Closing of $10.8 Million Offering

Jul 29, 2024, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10.8 Million Offering

CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 1 year ago

CEL-SCI Announces Pricing of $10.8 Million Offering

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Jul 26, 2024, 8:23 AM EDT - 1 year ago

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

CEL-SCI Appoints Robert Watson as Chairperson of the Board

Jul 8, 2024, 9:15 AM EDT - 1 year ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

May 16, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

May 8, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

Apr 16, 2024, 9:00 AM EDT - 1 year ago

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

Mar 19, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

CEL-SCI Corporation Issues Letter to Shareholders

Mar 6, 2024, 8:45 AM EST - 1 year ago

CEL-SCI Corporation Issues Letter to Shareholders

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

Feb 15, 2024, 8:00 AM EST - 1 year ago

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

Feb 13, 2024, 12:00 PM EST - 1 year ago

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

Feb 9, 2024, 8:30 AM EST - 1 year ago

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

Feb 6, 2024, 9:00 AM EST - 1 year ago

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

Jan 31, 2024, 9:00 AM EST - 1 year ago

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

Dec 22, 2023, 8:00 AM EST - 1 year ago

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

cruiser24
cruiser24 Aug. 7 at 4:00 PM
$CVM THANK You for stating exactly what I have seen while reading the outcome of the longest study of head and neck cancer. Not post of investors but found in medical journals. Like you it sounded like a fantastic opportunity for those confronted with the cancer and looking for the best option of treatment with shown greater outcomes. $CVM BULLISH
0 · Reply
cruiser24
cruiser24 Aug. 7 at 3:41 PM
Seems like a lot of different ones repeating Cel/sci. You know what they say. Where there is smoke there is fire. I sure am ready to roast me some hotdogs and marshmallows. $CVM BULLISH
1 · Reply
SmallCapGrowth
SmallCapGrowth Aug. 7 at 3:39 PM
$CVM CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules https://finance.yahoo.com/news/cel-sci-announces-closing-5-200500941.html
1 · Reply
cruiser24
cruiser24 Aug. 7 at 2:48 PM
$CVM
0 · Reply
cruiser24
cruiser24 Aug. 7 at 2:42 PM
$CVM I realize this article is old but it was published by Market screener not Cel-sci. It could be very damaging false reporting investor news I would think. IMO it is significant that this partnership is being reported by others besides Cel-sci Corporation only. It describes the details of the partnership in more detail as well. I’m not giving this as investor advice . Just thought it was worth noticing.
1 · Reply
Thebullrun
Thebullrun Aug. 7 at 2:13 PM
$CVM
1 · Reply
SmallCapGrowth
SmallCapGrowth Aug. 7 at 1:56 PM
$CVM CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules https://finance.yahoo.com/news/cel-sci-announces-closing-5-200500941.html #STOCKS #STOCKSTOBUY #INVESTORS #STOCKS #TRADER #CVM @Charles
1 · Reply
CashNCarry
CashNCarry Aug. 7 at 12:25 PM
$CVM
0 · Reply
Bjfrank87
Bjfrank87 Aug. 7 at 11:38 AM
$CVM the chart is screaming next move. A move upwards is needed to keep things looking bullish. Really hoping we don’t see a stop loss raid. A move back above $10 would be awesome.
0 · Reply
phoenix31415
phoenix31415 Aug. 7 at 8:39 AM
$CVM Yesterday's daily short sale volume was 51.25% (as reported by FINRA) and it seems that the shorts are trying hard to manipulate the market but the PPS went up 2.24%! The short borrow fee is at 56.26%!! and the number of currently shorted shares has dramatically increased to 1.54 million shares — that is an incredible 30.39% of the Float!! Furthermore, the short shares availability is down to 35000 shares. Note that on Fintel's Short Squeeze Leaderboard of the top 250 stocks most likely to squeeze, CVM is listed as #2!! With the recent SFDA and partner developments, it should just be a matter of time until Multikine will be approved and the heavy manipulation by the shorts will come to an end. I am so happy for all the cancer patients who will hopefully soon be able to profit from Multikine! GLTAL!!
1 · Reply
Princee25
Princee25 Aug. 7 at 5:04 AM
$CVM >15 year stock holder seen this 🐂 💩 played out …. So far appears to be very disappointing! Reverse stock trades to stay out of being delisted is the usual modus operandi!! I will be shocked if the shorts don’t win again lol
0 · Reply
HugeGains
HugeGains Aug. 7 at 12:22 AM
$CVM very nice consolidation here 7-9$ range . Holding strong after a powerful move up a that means there is more to come. Keep buying shares 20$ is nothing we can see 40$, even if u buy here that 11-30$ a share profit if we can reach 20-40$. I think it’s gonna happen when idk but im thinking with in 3-6 months. How bout u guys tell me your thoughts comment below
2 · Reply
ASF10
ASF10 Aug. 6 at 10:47 PM
$CVM Has anyone read the S-3/A document filed on August 5th and what it means?
1 · Reply
Bjfrank87
Bjfrank87 Aug. 6 at 7:41 PM
$CVM this is going to explode with some volume. Any day now….
1 · Reply
CashNCarry
CashNCarry Aug. 6 at 7:38 PM
$CVM Johnny D......Head ed that way again with negative RHETORIC.......He's got to get an invite to our CVM Las Vegas Party, when this thing POPS!!!!!! I want to meet this Gem!!
2 · Reply
stockinfocuz_
stockinfocuz_ Aug. 6 at 6:16 PM
$CVM
0 · Reply
Thebullrun
Thebullrun Aug. 6 at 6:13 PM
$CVM
1 · Reply
Thebullrun
Thebullrun Aug. 6 at 6:13 PM
$CVM
2 · Reply
ILikeDaStocks
ILikeDaStocks Aug. 6 at 5:27 PM
$CVM For weeks, my guess has been - partnership announced the week of Aug 11. I see a tiny indicator but not discussing here. Time will tell... 👍
1 · Reply
Johnyd
Johnyd Aug. 6 at 4:53 PM
$CVM .....Yet, nothing has been filed at the SFDA. I can't find it, can you?.... and she won'T . and she knows it. and you know it, EVRYBODY KNOWS IT!
0 · Reply
Johnyd
Johnyd Aug. 6 at 4:43 PM
$CVM......" The CEO loves to make false promises..." and he wants "revenge" ON YOU? makes sense? Call him up yet?
0 · Reply
dcpanda
dcpanda Aug. 6 at 4:28 PM
$CVM Will it be us? https://www.businessinsider.com/short-squeeze-stock-market-meme-stocks-retail-investors-25-8
4 · Reply